A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

A new type of PrEP injection, requiring only three injections a year, could be on the way. The FDA approved injections of cabotegravir in 2021 as a form of PrEP, to minimize the risk of acquiring HIV.

More encouraging news has been announced about the new, twice-yearly PrEP injection currently undergoing trials. Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has ...

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...

Wirth is the CEO of Amida Care. Crowley is the director of the O’Neill Institute’s Center for HIV and Infectious Disease Policy at Georgetown Law. In June, a clinical trial showed that a twice-yearly ...

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...

Nigerians have begun scrambling for Lenacapavir, a newly introduced injection for the prevention of Human Immunodeficiency ...

Twice-yearly lenacapavir (Sunlenca) substantially reduced HIV infection when used for preexposure prophylaxis (PrEP) in cisgender men and transgender or gender-nonbinary persons in the pivotal PURPOSE ...

The government is set to begin a nationwide rollout of a long-acting HIV prevention injection, Cabotegravir (CAB-LA), this week, following a successful one-year pilot phase. The rollout aims to ...